Skip to content
Bored Studies
RecruitingPhase 3

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

SpyGlass Pharma, Inc. · NCT07218796

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 22+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
400
US sites recruiting
1
Study start
October 28, 2025
Record last updated
October 20, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Being studied: Bimatoprost Implant System; SpyGlass IOL; Timolol Maleate Ophthalmic Solution, 0.5%; Commercial IOL

Conditions: Cataract; Glaucoma; Ocular Hypertension

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension
  • Planned removal of cataract
  • Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception

Exclusion Criteria

  • Uncontrolled systemic disease
  • History of incisional/refractive corneal surgery
  • Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma
  • History of incisional glaucoma surgery or intraocular injections
  • Other ocular diseases, pathology, or conditions

Recruiting US locations

  • R and R Eye Research, LLC

    San Antonio, TX 78229

    Site contact: Clinical Research Coordinator · 2104242584 · maggie@eye-assoc.com

Study contacts (from the official record)

  • Director, Clinical Affairs · 949-284-6904 · clinical@spyglasspharma.com
All heart & blood pressure studies in Texas →
Evaluation of the Safety and Efficacy of the Bimatoprost Implant… (NCT07218796) | Bored Studies